Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: A 16-week, randomized, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 699-702

  Ross, S ^a   Thamer, C ^b   Cescutti, J ^c   Meinicke, T ^b   Woerle, H J ^b   Broedl, U C ^b  

^a LMC Endocrinology Centres   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM   (France)

Author keywords

Empagliflozin; Glycaemic control; Metformin; Once daily; Twice daily

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMMEDIATE RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; ADULT; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TREATMENT OUTCOME;

EID: 84931955600     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12469     Document Type: Article

References (9)

1. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospect Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
3. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
4. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 2015; 12: 78-89.
5. Hundal RS, Krssak M, Dufour S etal. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
6. Haering HU, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659.
7. Ridderstråle M, Andersen KR, Zeller C etal. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-670.
8. Merker L, Haering HU, Christiansen AV etal. Empagliflozin as add-on to metformin in patients with type 2 diabetes (EMPA-REG EXTEND™ MET). Diabetes 2014; 63(Suppl. 1): A278 [1074-P].
9. Macha S, Brand T, Meinicke T, Link J, Broedl UC. Pharmacokinetics and pharmacodynamics of twice daily and once daily regimens of empagliflozin in healthy volunteers. Clin Pharm Drug Dev 2014; 3(Suppl. 1): 4.